Kinnunen PT, et al. - Since in vivo findings indicate that anticoagulants have anticancer properties, researchers examined the link between anticoagulant use and breast cancer survival in this nationwide study. They used the national prescription database to select all anticoagulants used from 1995 to 2015 in women (n = 73,170) diagnosed with invasive breast cancer in Finland between 1995 and 2013; they selected women from the Finnish Cancer Registry. They found an increased risk of breast cancer death in relation to postdiagnostic anticoagulant use. The risk was particularly high for low-molecular weight heparin, although the influence vanished in long-term users. Experts concluded that breast cancer survival is not clinically benefitted by anticoagulant use; however, potential survival benefits might be masked by the link between thrombosis and cancer.